BioSpace News Archive

Retailer’s Free Prescription program milestone marks its commitment to helping communities, saving customers more than $650 million

Catalyst Biosciences, Inc. (Nasdaq: CBIO) a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that Nassim Usman, Ph.D., president and chief executive officer, will present a corporate overview at the Annual BIO CEO & Investor Conference, being held in New York City on February 11-12, 2019.

Roger Sharma, Emanate Health’s Chief Financial Officer and Executive Vice President, has been named to the national list of “100 Hospital and Health System CFOs to Know” by Becker’s Hospital Review in 2019—one of only two CFOs to be recognized in Los Angeles County.

Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it had appointed Eric McDade, DO, a board-certified cognitive neurologist, as its next member to its Scientific Advisory Board.

Avion Pharmaceuticals, LLC, a specialty pharmaceutical company, has announced the license and commercialization agreement with ROMEG Therapeutics, LLC, for the exclusive rights to launch Gloperba – an oral solution for adults suffering from gout – in the United States

Seattle Genetics, Inc. reported financial results for the second quarter and six months ended June 30, 2019.

BioPharmX Corporation, a specialty pharmaceutical company focused on developing innovative medical dermatology products, announces the appointment of Steven M. Bosacki, a 20 year pharmaceutical industry veteran, as its Chief Operating Officer.

While drug-impaired driving has been illegal in Canada for more than 90 years, too many irresponsible individuals continue to put many lives at risk by driving impaired.

Puma Biotechnology, Inc. announced that its licensing partner Knight Therapeutics Inc. has received marketing authorization from Health Canada to commercialize NERLYNX® in Canada for the extended adjuvant treatment of women with early stage hormone receptor positive, HER2-overexpressed/amplified breast cancer within one year after completion of trastuzumab-based adjuvant therapy.

10:00 – 10:30 a.m.: Minister Petitpas Taylor will announce new federal government funding to address the opioid crisis and emerging drug threats.